The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting significant weight loss – they exhibit intriguing differences in their pharm